Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Hologic's annualizedNet Income for the quarter that ended in Dec. 2025 was €612 Mil. Hologic's average total tangible assets for the quarter that ended in Dec. 2025 was €4,168 Mil. Therefore, Hologic's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 14.68%.
The historical rank and industry rank for Hologic's Return-on-Tangible-Asset or its related term are showing as below:
FRA:HO1'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -8.63 Med: 17.04 Max: 51.92
Current: 11.79
During the past 13 years, Hologic's highest Return-on-Tangible-Asset was 51.92%. The lowest was -8.63%. And the median was 17.04%.
FRA:HO1's Return-on-Tangible-Asset is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.62
vs FRA:HO1: 11.79
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Hologic Return-on-Tangible-Asset Related Terms
Hologic Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Hologic's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HO1 vs WST, COO, ALGN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Hologic's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hologic Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hologic's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Hologic's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 14.68% mean?
Hologic (FRA:HO1) has a Return-on-Tangible-Asset of 14.68% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hologic and its competitors. This is 14% below median its historical median of 17.04.
Is Hologic's Return-on-Tangible-Asset too high?
Hologic's current Return-on-Tangible-Asset of 14.68% is 14% below median its 10-year median of 17.04. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.62. Hologic's value of 14.68% is 2267.7% above this industry median. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's Return-on-Tangible-Asset compare to WST and COO?
Hologic's Return-on-Tangible-Asset of 14.68% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Asset is 0.62. Hologic's value of 14.68% is 2267.7% above this benchmark. While the company's 10-year median is 17.04 vs. the industry median of 0.62, Hologic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.62, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hologic's current Return-on-Tangible-Asset of 14.68% is 2267.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Hologic and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hologic's current Return-on-Tangible-Asset is 14.68%, which is 14% below median its own 10-year median of 17.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (FRA:HO1) has a current Return-on-Tangible-Asset of 14.68%. The stock's GF Value™ is €70.17, compared to a current price of €65.00 — trading 7.4% below its estimated fair value. The current Return-on-Tangible-Asset is 14.68%, which is 14% below median its 10-year median of 17.04 and 2267.7% above the Medical Devices & Instruments industry median of 0.62. Hologic's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Hologic (FRA:HO1), the current Return-on-Tangible-Asset is 14.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hologic (FRA:HO1) Overvalued in 2026?
Based on GuruFocus' analysis, Hologic stock appears to be undervalued.
The current stock price of €65.00 is trading 7.4% below its estimated GF Value™ of €70.17.
Key valuation signals for FRA:HO1:
Return-on-Tangible-Asset: 14.68% (14% below median its 10-year median of 17.04)
GF Value™: €70.17 vs. price of €65.00 (7.4% below fair value)
Industry Position: 2267.7% above the Medical Devices & Instruments median
No single metric tells the full story. See the FRA:HO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score
Get the complete analysis for FRA:HO1
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HO1 has been successfully added to your 
